LPCNのチャート
LPCNの企業情報
| symbol | LPCN |
|---|---|
| 会社名 | Lipocine Inc (New) （リポシン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men''s and women''s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate LPCN 1021 is an oral testosterone replacement therapy (TRT) designed for twice-a-day dosing and is in Phase III testing. The Company''s additional pipeline candidates include LPCN 1111 an oral testosterone therapy product targeted for once daily dosing which is in Phase II testing and LPCN 1107 an oral therapy for the prevention of preterm birth which is in Phase I testing. These products are based on its Lip''ral promicellar drug delivery technology platform. Lip''ral promicellar technology is a technology based on lipidic compositions which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs. リポシンは、米国の特殊医薬品会社。男性と女性の健康分野の医薬品開発のために、経口薬物技術を用いる。同社の主要製品には、男性のテストステロン補充のための「LPCN 1021」とテストステロン治療のための「LPCN 1111」、女性の早産予防のために使用される「LPCN 1107」がある。 lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah. |
| 本社所在地 | 675 Arapeen Drive Suite 202 Salt Lake City UT 84108 USA |
| 代表者氏名 | Mahesh V. Patel Mahesh V. Patel |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 801-994-7383 |
| 設立年月日 | 40817 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 14人 |
| url | https://www.lipocine.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/lpcn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.94595 |
| 終値（lastsale） | 1.34 |
| 時価総額（marketcap） | 28494482.26 |
| 時価総額 | 時価総額（百万ドル） 25.73009 |
| 売上高 | 売上高（百万ドル） 0.42803 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15.76919 |
| 当期純利益 | 当期純利益（百万ドル） -2.80731 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Lipocine Inc revenues increased from $0K to $428K. Net loss decreased 45% to $6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 62% to $2.6M (expense) Stock-based Compensation in SGA decrease of 32% to $581K (expense). |
LPCNのテクニカル分析
LPCNのニュース
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday''s Mid-Day Session 2023/05/11 17:46:07 Benzinga
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM ) gained 109.8% to $1.06 after reporting a rise in Q1 sales. VCI Global Limited (NASDAQ: VCIG ) shares jumped 63.6% to $5.32. VCI Global reported application for dual listing on Upstream. Polar Power, Inc. (NASDAQ: POLA ) jumped 63.5% to $1.6847 after the company unveiled new line of mobile electric vehicle chargers. Jaguar Health, Inc. (NASDAQ: JAGX ) rose 47.2% to $1.06. Canalevia-CA1, Jaguar Animal Health''s FDA conditionally approved drug for chemotherapy-induced diarrhea in dogs, is now available from Chewy. Minim, Inc. (NASDAQ: MINM ) gained 33% to $6.14. Absolute Software Corporation (NASDAQ: ABST ) shares gained 32.3% to $11.36 after the company announced it will be acquired by Crosspoint Capital Partners for an enterprise value of $870 million. Organogenesis Holdings Inc. (NASDAQ: ORGO ) surged 30% to $2.73 followin strong quarterly sales. Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN ) climbed 29.2% to $36.18 after the company issued strong Q2 guidance.
Recap: Lipocine Q1 Earnings 2023/05/11 12:25:10 Benzinga
Lipocine (NASDAQ: LPCN ) reported its Q1 earnings results on Thursday, May 11, 2023 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Lipocine missed estimated earnings by 100.0%, reporting an EPS of $-0.04 versus an estimate of $-0.02. Revenue was … Full story available on Benzinga.com
Lipocine GAAP EPS of -$0.04 misses by $0.01 2023/05/11 10:49:36 Seeking Alpha
Lipocine press release (LPCN): Q1 GAAP EPS of -$0.04 misses by $0.01.
Lipocine: Q1 Earnings Snapshot 2023/05/11 10:22:31 WTOP
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Lipocine Inc. (LPCN) on Thursday reported a loss of $3.9…
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 2023/05/11 10:00:00 PR Newswire
SALT LAKE CITY, May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first…
Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket 2023/04/04 12:04:58 Benzinga
Gainers AMC Entertainment Hldg Pref Equity Units (NYSE: APE ) gained 28.4% to $1.90 in pre-market trading. AMC Entertainment Holdings stated it agreed to settle litigation and move forward with converting its preferred stock into common shares. Butterfly Network, Inc. (NASDAQ: BFLY ) jumped 26.2% to $2.36 in pre-market trading after the company received 510(k) clearance for AI-Enable Auto B-Line Counter. Addex Therapeutics Ltd (NASDAQ: ADXN ) gained 15.7% to $1.15 in pre-market trading. Addex published dipraglurant data showing in vivo efficacy on motor and non-motor symptoms of Parkinson''s disease. Meta Materials Inc. (NASDAQ: MMAT ) shares climbed 13.2% to $0.5565 in pre-market trading after jumping 20% on Monday. Meta Materials recently signed a joint development agreement for NPORE battery separator materials with a confidential global Top 10 battery OEM. Clever Leaves Holdings Inc (NASDAQ: CLVR ) climbed 12.3% to $0.40 in pre-market trading. The company recently posted upbeat Q4 results.
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 2023/04/03 12:00:00 Kwhen Finance
Lipocine Inc. (NASDAQ: LPCN) Could Soar To Much Higher Prices In Coming Months 2023/03/13 13:30:00 Marketing Sentinel
In the last trading session, 1.97 million Lipocine Inc. (NASDAQ:LPCN) shares changed hands as the company’s beta touched 1.00. With the company’s per share price at $0.31 changed hands at -$0.11 or -26.79% during last session, the market valuation stood at $37.14M. LPCN’s last price was a discount, traded about -509.68% off its 52-week high … Lipocine Inc. (NASDAQ: LPCN) Could Soar To Much Higher Prices In Coming Months Read More »
Lipocine GAAP EPS of -$0.13 in-line, revenue of $0.5M misses by $0.91M 2023/03/10 14:31:06 Seeking Alpha
Lipocine press release (LPCN): FY GAAP EPS of -$0.13 in-line.Revenue of $0.5M (-96.9% Y/Y) misses by $0.91M.As of December 31, 2022, Lipocine had $32.5 million of unrestricted cash,…
Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock 2023/03/10 13:30:00 Benzinga
SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company''s common stock held of record as of 5:00 p.m. Eastern Time on March 24, 2023 . The shares of Series B Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on March 24, 2023 . The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company''s common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.
Is Lipocine Inc. (LPCN) a threat to investors? 2022/09/28 12:24:00 US Post News
As of Tuesday, Lipocine Inc.’s (NASDAQ:LPCN) stock closed at $0.39, down from $0.44 the previous day. While Lipocine Inc. has underperformed by -11.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LPCN fell by -64.68%, with highs and lows ranging from $1.89 to $0.43, whereas the […]
Lipocine Inc. (NASDAQ: LPCN) Is Under Pressure Due To Weak Fundamental Momentum. 2022/09/28 11:30:00 Marketing Sentinel
In the last trading session, 1.1 million Lipocine Inc. (NASDAQ:LPCN) shares changed hands as the company’s beta touched 0.52. With the company’s per share price at $0.39 changed hands at -$0.05 or -11.85% during last session, the market valuation stood at $34.00M. LPCN’s last price was a discount, traded about -384.62% off its 52-week high … Lipocine Inc. (NASDAQ: LPCN) Is Under Pressure Due To Weak Fundamental Momentum. Read More »
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% 2022/09/26 13:29:12 Seeking Alpha
Lipocine (LPCN) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system ((CNS)) disorders.LPCN…
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference 2022/09/22 20:10:00 PR Newswire
SALT LAKE CITY, Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip''ral platform to augment therapeutics through effective oral delivery by developing differentiated products relative to standard of care,…
Boom Or Bust: Where Is Lipocine Inc. (NASDAQ: LPCN) Stock Headed Next? 2022/09/10 16:00:00 Marketing Sentinel
Lipocine Inc. (NASDAQ:LPCN)’s traded shares stood at 0.48 million during the last session, with the company’s beta value hitting 0.48. At the close of trading, the stock’s price was $0.51, to imply a decrease of -5.71% or -$0.04 in intraday trading. The LPCN share’s 52-week high remains $1.89, putting it -270.59% down since that peak … Boom Or Bust: Where Is Lipocine Inc. (NASDAQ: LPCN) Stock Headed Next? Read More »